Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
US Department of Justice
Farmers Insurance
Argus Health
Julphar
Deloitte
Cipla
Daiichi Sankyo

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IVERMECTIN

« Back to Dashboard

Clinical Trials for Ivermectin

Trial ID Title Status Sponsor Phase Summary
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed Universidad del Valle, Guatemala Phase 2 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed University of Alabama at Birmingham Phase 2 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00127504 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed Centers for Disease Control and Prevention Phase 2 The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
NCT00207753 Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections Completed Universidad del Valle, Guatemala N/A The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.
NCT00207753 Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections Completed Centers for Disease Control and Prevention N/A The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.
NCT00215280 Epidemiology and Control of Mansonella Perstans Infection in Uganda Completed Ministry of Health, Uganda N/A Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ivermectin

Condition Name

Condition Name for Ivermectin
Intervention Trials
Lymphatic Filariasis 12
Onchocerciasis 9
Head Lice 7
Scabies 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ivermectin
Intervention Trials
Filariasis 18
Elephantiasis 17
Elephantiasis, Filarial 16
Onchocerciasis 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ivermectin

Trials by Country

Trials by Country for Ivermectin
Location Trials
United States 57
France 15
Ghana 5
United Kingdom 4
Uganda 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ivermectin
Location Trials
Florida 9
California 9
Texas 4
Tennessee 4
Arkansas 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ivermectin

Clinical Trial Phase

Clinical Trial Phase for Ivermectin
Clinical Trial Phase Trials
Phase 4 11
Phase 3 20
Phase 2/Phase 3 3
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ivermectin
Clinical Trial Phase Trials
Completed 33
Recruiting 16
Not yet recruiting 12
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ivermectin

Sponsor Name

Sponsor Name for Ivermectin
Sponsor Trials
Washington University School of Medicine 9
London School of Hygiene and Tropical Medicine 7
University Hospitals Cleveland Medical Center 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ivermectin
Sponsor Trials
Other 109
Industry 21
NIH 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Citi
Chubb
Deloitte
Mallinckrodt
Queensland Health
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.